Renal Cell Carcinoma – Unmet Need – Unmet Need – Advanced or Metastatic Renal Cell Carcinoma (US/EU)
The treatment of advanced or metastatic renal cell carcinoma is dominated by immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda, BMS’s Opdivo and Yervoy) and small-molecule tyrosine kinase inhibitors (e.g., Ipsen’s Cabometyx, Eisai’s Lenvima / Kisplyx). However, the five-year survival rate for patients diagnosed with advanced or metastatic renal cell carcinoma is only 18% (SEER, 2024), highlighting the need for therapies that elicit long-term responses and improve survival. Furthermore, current treatments are associated with serious safety concerns, and no biomarker-driven therapies are available, leaving an unmet need for less-toxic treatments and the identification of predictive markers to help physicians select the most appropriate treatment for each patient.
QUESTIONS ANSWERED
- Which attributes most influence physicians’ prescribing decisions in the treatment of advanced or metastatic renal cell carcinoma?
- How do medical oncologists rate the performance of current therapies, such as Opdivo + Yervoy and Keytruda + Inlyta, on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need in the treatment of advanced or metastatic renal cell carcinoma?
- What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for advanced or metastatic renal cell carcinoma?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in January 2024
Key drugs: Cabometyx, Inlyta, Keytruda, Lenvima / Kisplyx, Opdivo, Yervoy
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
KEY FEATURE
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
